ABSTRACT Myostatin, a member of the transforming growth factor-β (TGF-β) superfamily, is a potent negative regulator of skeletal muscle growth. The objective of this study was to produce a monoclonal anti-myostatin antibody and to examine the effects of in ovo administration of the antibody on posthatch broiler growth and muscle mass. The mature form of myostatin was expressed in Escherichia coli and used as an immunogen in producing a monoclonal antibody against myostatin. One hybridoma clone (mAb-c134) that showed the strongest affinity to the immunogen in Western blot analysis was used in producing a large quantity of monoclonal anti-myostatin antibody. In Western blot analysis, this antibody showed a strong binding affinity to commercially available mature myostatin and demonstrated a certain level of crossreactivity with recombinant human BMP2 but not with
INTRODUCTION
Myostatin, a member of the transforming growth factor-β (TGF-β) superfamily of growth factors, is a negative regulator of skeletal muscle growth. For example, knockout of the myostatin gene caused a more than 2-fold increase in muscle mass in mice . Nonfunctional mutation in myostatin gene was reported in double-muscled cattle that are characterized by a greater muscle mass than normal cattle (Grobet et al., 1997; Kambadur et al., 1997 ).
Myostatin appears to suppress both muscle cell hyperplasia and hypertrophy. In skeletal muscle cell cultures, addition of recombinant myostatin or overexpression of myostatin inhibited the proliferation of myoblasts (Thomas et al., 2000; Taylor et al., 2001) . The inhibitory 1062 recombinant human TGF-β3 or porcine TGF-β1. Competitive ELISA demonstrated binding of the antibody to the native form of mature myostatin in solution. To examine the effects of in ovo administration of the mAb-c134 antibody, eggs were injected once with 40 g of mAb-c134 in 50 mL of PBS either into the albumen or yolk on d 3 of incubation. Controls received no injection. After hatching, chicks were raised for 35 d. Broilers from eggs that had the antibody injected into the yolk had significantly heavier body (4.2%) and muscle (5.5%) mass than the controls in both male and female birds. In contrast, no significant effects on body and muscle mass were observed when the mAb-c134 antibody was injected into the albumen. The results of this study suggest that immunoneutralization of myostatin during embryonic development is a potential means to improve growth potential of broilers.
role of myostatin on myoblast proliferation explains the hyperplasia of muscle fibers observed in mice and cattle carrying a nonfunctional myostatin gene. The inhibition of myoblast proliferation by myostatin appears to be through the prevention of the progression of myoblasts from the G1-to S-phase of the cell cycle regulated by Rb protein hypophosphorylation (Thomas et al., 2000) . Similarly, upregulation of cyclin dependent kinase inhibitor p21 and downregulation of cyclin-dependent kinase (Cdk2) was observed in myostatin-added cell culture (Thomas et al., 2000) . The upregulation of p21 was also observed in C 2 C 12 muscle cell cultures overexpressing myostatin (Rios et al., 2001) .
In addition to the inhibitory role of myostatin in myoblast proliferation (hyperplasia), studies indicated that myostatin has a role in postnatal skeletal muscle growth and maintenance. Anti-myostatin antibody administration to adult mice induced hypertrophy of muscle fibers (Whittemore et al., 2003) . In dystrophic mice, administration of anti-myostatin antibody ameliorated the muscular dystrophic condition as evidenced by an increase in body mass, whole muscle cross-sectional, and muscle fiber areas (Bogdanovich et al., 2002) . When conditional myostatin knockout mice exhibiting a postnatal inactivation of myostatin were generated (Grobet et al., 2003) , dramatic increases in muscle mass were observed. The increase in skeletal muscle mass in the conditional myostatin knockout was primarily due to hypertrophy of skeletal muscle fibers. Conversely, overexpression of myostatin in mice induced an overall decrease in muscle mass (Zimmers et al., 2002) . In addition, both animal and human studies have shown that a negative correlation exists between the level of myostatin and muscle mass under various physiological or pathological conditions that induce muscle loss or gain (Gonzalez-Cadavid et al., 1998; Carlson et al., 1999; Kirk et al., 2000; Lalani et al., 2000; Mendler et al., 2000; Wehling et al., 2000; Reardon et al., 2001; Welle et al., 2002; Armand et al., 2003) .
These results indicate that suppressing the biological activity of myostatin either during embryonic development or postnatal growth will be an effective strategy to improve skeletal muscle growth and carcass composition in farm animals. Although anti-myostatin antibodies have been effectively used as a vehicle to suppress the biological activity of myostatin in mice (Bogdanovich et al., 2002; Whittemore et al., 2003) , this approach has not been tested in farm animals. In chickens, increased levels of myostatin mRNA expression coincided with the myoblast proliferation during embryonic development (Kocamis et al., 1999a) , indicating a role of myostatin in skeletal muscle development in this species. Therefore, we examined whether immnoneutralization of myostatin via in ovo administration of anti-myostatin antibody would modulate posthatch broiler growth. Our results demonstrate that in ovo administration of anti-myostatin antibody into the yolk increases body mass and skeletal muscle growth in broilers.
MATERIALS AND METHODS

Reagents and Chemicals
Ampicillin, chloramphenicol, IPTG, lysozyme, LB Agar, and LB broth were purchased from Fisher Scientific (Pittsburgh, PA). Anti-mouse IgG conjugated to alkaline phosphate, anti-rabbit IgG conjugated to alkaline phosphate, anti-goat IgG conjugated to alkaline phosphate, and BCIP/NBT liquid substrate were purchased from Sigma (St. Louis, MO). Recombinant mouse GDF-8, recombinant human BMP2, recombinant human TGF-β3, and porcine TGB-β1 were purchased from R&D Systems (Minneapolis, MN). The PCR reaction mixture was purchased from Gibco BRL Inc. (Rockville, MD). Unless otherwise indicated, all other chemicals and reagents were purchased from Fisher Scientific or Sigma.
Construction of Myostatin Fragment Expression Vector and Expression of Recombinant Myostatin
Messenger RNA isolated from 5-wk broiler pectoralis muscle were used to synthesize cDNA using SuperScript II RNase H -reverse transcription (Gibco BRL Inc.). The cDNA reaction mixture was used to amplify a 369-bp Cterminal fragment of chicken myostatin cDNA in a PCR reaction. Primers were designed on the basis of the reported chicken myostatin mRNA sequence (GeneBank Accession number, AF019621). The forward and reverse primers were 5′-GAGGTCAGAGTTACAGACACA-3′ and 5′-TCATGAGCACCCGCAACGATC-3′, respectively. The primer combination was designed to yield a PCR product corresponding to bases 760 to 1,125 of chicken myostatin mRNA sequence that encodes the 122 amino acid C-terminal myostatin. The amplified myostatin cDNA fragment was purified from the PCR reaction mixture and subsequently inserted into a cloning vector (pCRT7/NT-TOPO, Invitrogen, Carlsbad, CA) following the manufacturer's instruction. The plasmid vectors containing myostatin cDNA were introduced by heat shock into competent Escherichia coli for the characterization of construct, propagation and maintenance. Clones were identified for correct insertion using PCR and restriction analysis of the plasmids. After the initial screening, plasmids of selective clones were subjected to DNA sequence analysis for the final confirmation of correct orientation.
Plasmids containing the correctly inserted myostatin cDNA fragment were isolated, and introduced into expression competent E. coli [BL21 (DE3) pLysS One Shot, Invitrogen, Carlsbad, CA] harboring the lambda DE3 lysogen that carries the T7 RNA polymerase under the control of the lacUV5 promoter. The transformation mixture was added to LB medium containing 100 g of ampicillin/mL and 34 g of chloramphenicol/mL for overnight growth at 37°C with vigorous shaking. This culture was used to inoculate prewarmed 200 mL of LB medium containing 100 g of ampicillin/mL and 34 of chloramphenicolg/mL. Myostatin expression was induced at an OD 600 of 0.6 to 0.7 by adding IPTG to 1 mM. After 4 h, cells were harvested by centrifugation at 5,000 × g for 20 min and stored frozen for later use. The expression of recombinant myostatin (molecular weight, 18.5 kDa) was confirmed by SDS-PAGE analysis.
Isolation and Solubilization of Recombinant Myostatin
The pelleted cells from 200 mL of culture were resuspended in 40 mL of 20 mM phosphate buffer containing 500 mM NaCl (pH 7.8) and incubated at room temperature for 15 min after adding 100 g of egg white lysozyme/mL. Cells were lysed by the combination of sonication and 3 cycles of flash freeze (liquid nitrogen) and thaw at 37°C. The insoluble material was pelleted by centrifugation at 5,000 × g for 20 min, followed by washing twice in lysis buffer containing 50 mM potassium phosphate, 400 mM NaCl, 100 mM KCl, 10% glycerol, 0.5% Triton X-100, and 10 mM imidazole (pH 7.8). The pellet was washed again twice with distilled water to remove salts and detergents. About 12 mg of purified inclusion body proteins were harvested from 200 mL of culture, and this final sediment was used for solubilization. (200, 116, 97.4, 66, 45, 31, 21.5, 14 .4, and 6.5 kDa). The solubilized myostatin was used as an antigen for monoclonal antibody production and as a coating antigen in ELISA.
Ten milligrams of inclusion bodies containing recombinant myostatin was suspended in 10 mL of 50 mM Tris/ HCl buffer (pH 8.0) containing 4 M urea and 5 mM dithiothretiol (Suenaga et al., 1998) . Substantial amount of the recombinant myostatin dissolved in this solution; thus the supernatant was collected after centrifugation at 10,000 × g for 20 min. Solubilizations were repeated 4 times more by successive washing of the pellet with the solution just described until a significant drop in solubilization was observed by monitoring the protein concentration of supernatant at OD 280 (less than 0.1). The pooled solution (50 mL) containing solubilized myostatin fragment was dialyzed 5 times against a solution containing 0.25% (wt/ vol) sodium bicarbonate, 0.2% (wt/vol) α-lactose, and 0.2% (wt/vol) mannitol, pH 8.5 (BLM buffer, Langley et al., 1987) . The dialyzed solution was centrifuged at 10,000 × g for 20 min to remove precipitating materials and concentrated by ultrafiltration to yield a protein concentration of approximately 4 mg/mL. This solubilized myostatin ( Figure 1 ) was used as an antigen for monoclonal antibody production and as a coating antigen in ELISA during the initial screening of hybridoma cells for antimyostatin IgG production.
Production of Monoclonal Anti-Myostatin Antibody
Solubilized recombinant myostatin was sent to the Monoclonal Antibody Facility, University of Hawaii, to generate hybridoma cells using standard procedures described by Harlow and Lane (1988) . Initial screening of hybridoma cells secreting anti-mysotatin antibody was performed by ELISA. The coating antigen was the same recombinant myostatin used for immunization. Further screening was carried out by Western blot. Among 120 hybridoma clones generated, 6 clones demonstrated an affinity to the recombinant myostatin in Western blot analysis. The recombinant myostatin that we used as an immunogen ( Figure 1 ) contained a N-terminal fusion protein for use in protein purification processes. To ensure that the antibody has an affinity to an epitope in myostatin, not to epitopes in the fusion protein, we used Western blotting to select hybridoma clones that have a binding affinity to the recombinant myostatin containing no fusion protein. Based on its highest affinity to the antigen, one clone (c134) was selected for the production of a large quantity of monoclonal antibody from ascitic fluid. The ascitic fluid was subjected to protein A-affinity chromatography (Affi-gel protein A MAPS II kit, BioRad, Hercules, CA) to purify monoclonal anti-myostatin IgG (mAb-c134).
Competitive ELISA
The ELISA plate wells were covered with 50 L of the solubilized myostatin at a protein concentration of 20 g/ mL in PBS solution, pH 7.4, and incubated overnight at 4°C. After being washed with PBS, 100 L of blocking agent (1% BSA in PBS) was added to the plate, followed by 1 h of incubation at room temperature. After being washed twice with PBS, mixtures of 25 L of mAb-c134 (30 g/mL) plus 25 L of serially diluted commercial recombinant myostatin (GDF-8, R&D Systems, Minneapolis, MN) were added to the plate and then incubated 1 h at room temperature. The plate was washed 3 times with PBS-0.05% Tween. Then 50 L of alkaline phosphataseconjugated anti-mouse IgG (1:50,000) was added to the plate and incubated for 1 h at room temperature. After being washed 3 times with PBS-0.05% Tween, 50 L of pNPP was added to the plates and incubated for 30 min. The absorbance was measured at 405 nm. The binding inhibition by recombinant myostatin (GDF-8) was calculated by the method described previously (Kim and Kim, 1997) .
SDS-PAGE Analysis
The SDS-PAGE analysis was performed on mini gels (9 × 10 cm) by the method of Laemmli (1970) , using polyacrylamide gels in the presence of 0.1% SDS under reducing or nonreducing conditions. The gels were either stained with Sypro Ruby (BioRad) or Coomassie blue.
Western Blot Analyses
Western blot analyses were performed to determine the binding characteristics of the monoclonal anti-myostatin antibody (mAb-c134) and other 2 commercial anti-myostatin antibodies (R&D Systems and Santa Cruz Biotechnology Inc., Santa Cruz, CA). Proteins fractionated by SDS-PAGE were eletrophoretically transferred to a nitrocellulose membrane. After being blocked with 100 mM Tris buffer (pH 7.5) containing 0.9% NaCl and 0.1% Tween-20 (TBST), the membrane was incubated with antimyostatin antibodies for 2 h at room temperature. After washing with TBST, the membrane was incubated with a 1:5,000 dilution of appropriate secondary antibodies conjugated with alkaline phosphatase for 1 h at room temperature, followed by color development with the BCIP/NBT substrate.
In Ovo Injection of Monoclonal AntiMyostatin Antibody (mAb-c134)
Fertilized broiler eggs (180) all from the same breeder flock were obtained from a local hatchery and were randomly divided into 3 groups: no injection (control, 40 eggs), and injection into the albumen (albumen, 60 eggs) and the yolk (yolk, 60 eggs). Egg weights were between 57 and 67 g with mean values and standard deviations being 61.9 g ± 2.63 (control), 61.7 g ± 2.64 (albumen), and 61.7 g ± 2.54 (yolk). More eggs were allocated into the albumen and yolk groups because our preliminary studies (unpublished) and others (Kocamis et al., 1998 (Kocamis et al., , 1999b Ohta et al., 1999 ) indicated a lower hatchability for injected eggs. Our unpublished study showed that in ovo administration of buffer alone or nonimmune mouse IgG had no effect on posthatch growth of broilers; thus we did not include a group with buffer alone or nonimmune IgG.
On d 3 of incubation (38°C and 90% humidity), eggs were injected with 40 g of the mAb-c134 in 50 L of phosphate buffer into the albumen or yolk using a 3/8 inch, 25-gauge needle. Prior to injection, eggs were cleaned with 70% ethanol. A 2-mm hole was made at the center of the longitudinal axis of the egg for the albumen group and at the upper 1/3 part of the blunt end of the egg for the yolk group. After injection, the site was carefully disinfected with antimicrobial saturated paper wraps and sealed with adhesive tape. The eggs were then placed back into the incubator until hatching.
Animal Care
Egg incubation and animal care were approved by the Institutional Animal Care and Use Committee. After hatching, chicks were placed to battery pens equipped with electric heater. Initially 3 pens were randomly allocated in each group. Because the size of the pen was not adjustable, number of animals in each pen was adjusted as animals grew, resulting in a gradual increase in the number of pens for each group. Heater temperature was set to 35, 32, and 30°C in the first, second, and third week, respectively. After the third week, the heater was turned off, and the room temperature was maintained at 26.6°C in a thermostatically controlled building with 12L:12D light cycle. During the first 3 wk, chicks were fed a commercial broiler starter diet containing 22% crude protein, 1% lysine, and 0.45% methionine, and during the last 2 wk, they were fed a commercial grower diet containing 16.0% protein, 0.5% lysine, and 0.25% methionine. Water and diet were provided ad libitum. Weekly body weights were recorded. At 5 wk of age, birds were fasted for 3 h, weighed, and killed by CO 2 inhalation. The birds were then decapitated at the first cervical vertebra, bled, scalded at 56°C for 30 s, defeathered, and dressed. The abdominal contents were eviscerated, and heart, liver, spleen, and abdominal fat were separated and weighed. After recoding dressed weight, breast muscle was separated and weighed. Whole thighs and legs with bone in from both sides were also separated and weighed.
Statistical Analysis
The ANOVA was performed by GLM procedure using JMP software (SAS Institute, Cary, NC). Model included main effects of treatment, sex, and treatment × sex interaction. The Tukey honestly significant difference test was used to compare the means in treatment groups when a significant effect was observed (P ≤ 0.05).
RESULTS
Binding Characteristics of Monoclonal Anti-Myostatin Antibody (mAb-c134)
The monoclonal anti-myostatin antibody (mAb-c134) had an affinity to both the monomer and the dimer forms of mature myostatin (GDF-8) and appeared to have a higher affinity to the monomer than to the dimer based on the band intensity in Western blot analysis ( Figure  2 ). When 2 commercial anti-myostatin antibodies were tested, the commercial polyclonal anti-myostatin antibody (Santa-Cruz Biotechnology Inc.) that was raised against a peptide from the mature myostatin sequence showed a selective affinity only to the monomer form of myostatin but not to the dimer form (Figure 2, lane D) , whereas the other commercial anti-myostatin antibody (R&D Systems) that was raised against the whole myostatin molecule showed an affinity to both forms ( Figure  2, lane B) .
To determine whether the mAb-c134 was able to bind to the native form of myostatin in solution, we performed competitive ELISA using a commercially available myostatin (GDF-8) as a competing ligand and our recombinant myostatin as a coating antigen. The commercial myostatin, which was produced in a eukaryotic cell line, inhibited the binding of mAb-c134 to the coating antigen in a dose-dependent manner (Figure 3) , indicating that the mAb-c134 was able to bind the native form of myostatin in solution.
Cross reactivity of mAb-c134 with some members of the TGF-β superfamily was tested by Western blotting. The mAb-c134 cross-reacted with recombinant human BMP2 (rhBMP2) but not with recombinant human TGF-β3 and porcine TGF-β1 (Figure 4) . Other 2 commercial anti-myostatin antibodies showed similar binding characteristics ( Figure 4C and D) . Estimating from the band intensity in Western blotting, the binding affinities of antimyostatin antibodies to rhBMP2 appeared to be lower than the binding affinities to myostatin. Western blot analysis of binding affinity of mAb-c134, a hybridoma clone, to native myostatin. One hundred nanograms of commercial myostatin that contained 5 g of BSA as a carrier protein (GDF-8, R&D Systems, Minneapolis, MN) under reduced (+MCE) or nonreduced conditions (−MCE) were subjected to 15% SDS-PAGE and visualized with Sypro Rubby (BioRad, Hercules, CA) staining (panel A). After transfer and blocking, membranes were incubated with commercially available anti-myostatin antibodies (panels B and D, R&D Systems and Santa-Cruz Biotechnology Inc., Santa Cruz, CA, respectively) or mAb-c134 (panel C). Upper and lower arrowheads indicate myostatin dimer and monomer, respectively. MCE = β-mercaptoethanol. Primary antibody concentrations were as follows: 1 g/mL for panel D and 0.3 g/mL for panels B and C. Nonstained protein standards were used for the gel for Sypro Rubby staining, and prestained protein standards were used for the gels for Western blot analysis.
Myostatin is known to be produced exclusively in skeletal muscles (McPherron et al., 1997), thus we did Western blotting with skeletal muscle to examine the ability of mAb-c134 to recognize myostatin in whole muscle homogenate and the cross-reactivity of mAb-c134 with other skeletal muscle proteins. The mAb-c134 showed strong affinity to protein bands at around 50 and 37 kDa and weak affinity to protein bands at around 30 and 17 kDa, but no affinity was detected at the band area where the mature myostatin was expected to locate ( Figure 5 ). The binding pattern of commercial anti-myostatin anibody (R&D Systems) was identical to that of mAb-c134 in skeletal muscle (C in Figure 5 ).
Effects of In Ovo Administration of mAb-c134 on Posthatch Broiler Growth and Muscle and Organ Weights
The hatchability after in ovo injection of mAb-c134 and numbers of male and female killed at 5 wk posthatch are shown in Table 1 . Hatchability was decreased by in ovo injection (75% and 67% for albumen and yolk groups vs. 90% for control). Some posthatch deaths occurred in injection groups during the early growth phase. When unhatched eggs were examined, we observed embryonic deaths occurred at various stages of the embryonic development. Lower hatchability was also reported after in ovo injection of IGF-I or amino acids (Kocamis et al., 1998 (Kocamis et al., , 1999b Ohta et al., 1999) . The extent of reduced hatchability observed in this study is comparable to that of the previously mentioned reports. Both the site of injection and the age of embryo at the time of injection affected the hatchability of chicks (Kocamis et al., 1998 (Kocamis et al., , 1999b Ohta et al., 1999; Ohta and Kidd, 2001 ). For instance, injections into the chorioallantonic membrane and amnionic cavity at 7 d incubation resulted in 0% hatchability (Ohta and Kidd, 2001 ).
The effect of in ovo administration of mAb-c134 on broiler growth is summarized in Table 2 . Regardless of treatment, a significant sex effect was observed on body weight, starting 2 wk after hatch. A significant treatment effect on body weight was also observed throughout the Competitive ELISA demonstrating the binding of mAbc134, a hybridoma clone, to recombinant native myostatin. The ELISA plate wells were covered with solubilized myostatin (20 g/mL) produced in our laboratory. The concentration of mAb-c134 in the competitive assay was determined based upon saturation assay and was 30 g/mL. Commercially available recombinant myostatin (GDF-8, R&D Systems, Minneapolis, MN) was diluted in PBS containing 0.1% BSA from 800 nM to 51.2 pM as a competing ligand. Alkaline phosphateconjugated anti-mouse IgG and pNPP were used as a secondary antibody and a substrate, respectively. The absorbance was measured at 405 nM. n = 2. Cross-reactivity of anti-myostatin antibodies with some members of the transforming growth factor (TGF)-β superfamily. One hundred nanograms of rmGDF-8, rhTGF-β3, rhBMP2, and pTGF-β1 were subjected to 15% SDS-PAGE in reduced condition and visualized with Sypro Rubby (BioRad, Hercules, CA) staining (panel A). After transfer and blocking, the membranes were incubated with either mAb-c134 (panel B) or commercially available polyclonal antibodies raised against mature myostatin (panels C and D, R&D Systems, Minneapolis, MN, and Santa Cruz Biotechnology Inc., Santa Cruz, CA, respectively). Primary antibody concentrations were as follows: 1 g/mL for monoclonal anti-myostatin antibody, 0.3 g/mL for antibody from R&D Systems, 1 g/mL for antibody from Santa Cruz Biotechnology.
5 wk growout period, but no treatment and sex interaction was observed. Regardless of sex, body weight of the yolk group was significantly heavier than that of the control or albumen groups throughout most of the growout period. The highest improvement was observed at 7 d with Figure 5 . Western blot analysis of binding characteristics of antimyostatin antibody in skeletal muscle. Commercially available recombinant myostatin (GDF-8) containing 0.1% BSA (R&D Systems, Minneapolis, MN) and chicken leg muscle homogenate were fractionated in a 15% SDS-PAGE in reduced condition, blotted, and probed with mAbc134 (panel B) and commercially available (antiGDF8, R&D Systems) polyclonal anti-myostatin antibody (panel C). Coomassie blue-stained SDS-PAGE gel is shown in panel A chicken leg muscle sample from a 19-d-old embryo was homogenized in 15 volumes of 40 mM Tris buffer (pH 7.5) containing 10 mM EDTA, 1 mM PMSF, 10 mM 2-mercaptoethanol, and 0.2% Triton X-100; then 10 mL of whole homogenate was loaded for fractionation (lane 3). 100 ng of recombinant myostatin was loaded (lane 2). The concentration of primary antibodies (mAb-c134 and antiGDF8) was 0.4 g/mL.
8.3%, and at 35 d it was 4.2%. No significant difference in body weight was observed between the control and albumen groups throughout the growout period. Table  3 summarizes the response in carcass, muscle, and organ weights. Regardless of sex, the yolk group had significantly heavier carcass (4.7%), leg muscle (5.5%), and breast muscle (5.5%) than the control group. The heart and abdominal fat weights of the yolk group were also significantly heavier than that of the control group. Dressing percentage, percentages of breast muscle, leg muscle, heart, and abdominal fat to body weight were not affected by the mAb-c134 administration. No significant differences in these parameters were observed between the control and albumen groups.
DISCUSSION
Immunoneutralization of myostatin as a potential approach to improve skeletal muscle growth has been demonstrated in laboratory animals (Bogdanovich et al., 2002; Whittemore et al., 2003) . In this study, we produced a monoclonal anti-myostatin antibody and examined whether in ovo administration of this antibody would affect posthatch skeletal muscle growth in broilers. Our hypothesis was that anti-myostatin antibody present in fertilized egg would be absorbed during embryonic development to modulate the biological activity of myostatin, resulting in altered skeletal muscle growth. Our results showed that the broilers hatched from eggs injected with anti-myostatin antibody in the yolk had enhanced growth and heavier skeletal muscles compared with control broilers, supporting our hypothesis.
Binding Characteristics of Monoclonal Anti-Myostatin Antibody (mAb-c134)
The monoclonal anti-myostatin antibody (mAb-c134) that was produced in this study using recombinant myo- statin showed an affinity to both the monomer and dimer forms of mature myostatin, whereas a commercial polyclonal antibody showed a selective affinity only to the monomer form of myostatin. These results are in agreement with our previous result (Jin et al., 2004) . Because the commercial polyclonal antibody that did not show an affinity to the dimer form of myostatin was generated against a peptide sequence of mature myostatin, it is postulated that the peptide used as an antigen in that antibody production was probably located in a region of the myostatin that is hidden during dimer formation.
Gel filtration of the solubilized recombinant myostatin that we used as an antigen in monoclonal antibody generation demonstrated that the recombinant myostatin existed as heterogeneous aggregates of various size (data not shown), indicating that the majority of the recombinant myostatin refolded into nonnative forms. This led us to question whether the antibody we produced would bind to the native form of myostatin in solution. Since our objective was to suppress myostatin's biological activity using this antibody, it was important to assure the binding ability of the mAb-c134 to the native form of myostatin. The result of competitive ELISA demonstrated that the mAb-c134 was able to bind the native form of myostatin, indicating that when injected into animal system, the mAb-c134 would bind to myostatin even though the competitive ELISA results could not predict the capability of the mAb-134 to inhibit the biological activity of myostatin.
The mAb-c134 along with other 2 commercial polyclonal anti-myostatin antibodies showed cross reactivity to the recombinant human BMP2 but not to recombinant human TGF-β3 and to porcine TGF-β1 in Western blotting, indicating that myostatin probably shares more structural homology with BMP2 than with TGF-β3 or Means not sharing the same superscript are different at P < 0.05.
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Data are least square means (SEM). Mean difference was analyzed by Tukey honestly significant difference test. **P < 0.01; *P < 0.05; †P < 0.1.
TGF-β1. It is interesting to note that BMP2 is not in the subgroup that myostatin belongs to, but TGF-β1 and -β3 are in the myostain subgroup (Lee, 2004) . Because the subgrouping is based on DNA sequence homology, the results indicate that the immuno-crossreactivity of members of the TGF-β superfamily is not necessarily related to the DNA sequence homology. The crossreactivity of the anti-myostatin antibodies with BMP2 suggests that caution should be exercised in estimating the levels of tissue or plasma myostatin using ELISA or Western blotting.
In Western blot analysis with skeletal muscle, the mAbc134 showed an affinity to 50, 37, 30 and 17 kDa proteins, but no affinity was detected at an area (12.5 kDa) where the mature myostatin was expected to locate, thus raising questions regarding the presence of mature myostatin in skeletal muscle and the nature of immunoreactive proteins present in skeletal muscle. Numerous studies reported the presence of myostatin-immunoreactive proteins with various molecular weights in skeletal muscle (Gonzalez-Cadavid et al., 1998; Sharma et al., 1999; Lalani et al., 2000; Sakuma et al., 2000; Wehling et al., 2000; Kawada et al., 2001; Berry et al., 2002) , but none of the reported myostatin-immunoreactive proteins had a molecular weight close to 12.5 kDa. In mouse serum, the presence of 12 kDa mature myostatin was confirmed by the combination of immunoprecipitation and LC-MS-MS methods (Hill et al., 2002) . Zimmers et al. (2002) also reported the presence of the 12 kDa mature myostatin in mouse serum. Assuming that the 12 kDa mature myostatin present in serum originated from skeletal muscle, the reason that we and others failed to demonstrate the presence of 12 kDa mature myostatin in skeletal muscle is probably related to low abundance of myostatin that escaped the detection limit of the current Western blot protocol with whole muscle preparations. It is tempting to assume that some of the 4 proteins that demonstrated affinity to mAb-c134 are various forms of myostatin undergoing posttranslational processing. However, those 4 proteins that demonstrated affinity to mAb-c134 were also present in cardiac muscle, liver, small intestine, and brain in our Western blot analysis of various tissues of chicken (data not shown), thus indicating that these myostatin-immunoreactive proteins could be nonspecific, cross-reactive proteins present in skeletal muscle. The organ percentage is relative to body weight. **P < 0.01; *P < 0.05; †P < 0.1.
Effects of In Ovo Administration of mAb-c134 on Posthatch Broiler Growth and Muscle Mass
Yolk IgG are transported intact from the yolk across the yolk sac into embryonic circulation via receptor-mediated mechanisms (Kramer and Cho, 1970; Kowalczyk et al., 1985) . Because we observed an increase in body and muscle mass in birds hatched from eggs injected with antimyostatin antibody into the yolk area, it is speculated that the anti-myostatin antibody was transported into the embryo and modulated the biological activity to enhance skeletal muscle development. The presence of IgG in fetal serum could be detected at 7 d after incubation, but almost 90% of the IgG absorption occurred during the last 3 d of incubation, and the maternal IgG lasted up to 2 to 3 wk after hatching (Kramer and Cho, 1970; Kowalczyk et al., 1985) . If the injected anti-myostatin antibody followed the same pattern of absorption as the maternal IgG, the anti-myostatin antibody was probably available in the embryo starting from a few days before hatching up to 2 or 3 wk after hatching. Because myostatin suppresses both the hyperplasia and hypertrophy of muscle fibers, the increase in muscle mass observed in this study could be due to either hyperplasia or hypertrophy of muscle fibers during the early growth period. Because the transfer of injected anti-myostatin antibody into the circulation of developing embryo is crucial for the anti-myostatin antibody to suppress the activity of myostatin, future studies need to verify the transfer of injected anti-myostatin antibody into the circulation of developing embryo.
Although the increase in skeletal muscle mass resulting from the intraperitoneal administration of anti-myostatin antibody in mice was from 11 to 30% (Whittemore et al., 2003) , the increase in skeletal muscle mass by the in ovo administration of anti-myostatin antibody in this study was about 5%. It is probable that the smaller increase in skeletal muscle mass observed in this study was related to the dose of anti-myostatin antibody injected into yolk; thus future studies with various doses are needed. Because the mAb-c134 demonstrated nonspecific affinity to various skeletal muscle proteins, it is questioned whether the nonspecific bindings interfere with the ability of mAbc134 to inhibit myostatin activity. Currently we do not have a clear explanation for this question, but we speculate that if the proteins demonstrating the nonspecific binding to mAb-c134 are intracellularly located, the extracellular interaction between mAb-c134 and myostatin would not likely be much affected.
Notably, the growth promoting effect was observed only when the anti-myostatin antibody was administered into the yolk but not when it was administered into the albumen, suggesting a possibly different mode of antibody absorption between the albumen and yolk. We did not track the passage of mAb-c134 after administration in this study, but from the current results it is speculated that enough mAb-c134, when injected into the yolk, passed into the embryo to modulate the biological activity of myostatin, although not enough of the mAb-c134 injected into the albumen passed into the embryo. Studies generally indicate that ovalbumin, the major component of egg white proteins, moves into the yolk probably via various routes (Sugimoto et al., 1999; Yoshizaki et al., 2002) . It was also reported that direct flow of some proteins present in egg white, such as ovomucoid ovoinhibitor, lysozyme, and ovotransferrin, occurred from egg white to embryo in chicken (Sugimoto et al., 1984 (Sugimoto et al., , 1996 (Sugimoto et al., , 1999 . Somatotropin or IGF-I, when injected into the albumen during embryonic development, improved posthatch growth rate in broilers (Kocamis et al., 1998 (Kocamis et al., , 1999b , indicating that certain proteins injected into the egg white during embryonic development can be absorbed by the embryo without being digested to exert their biological influence. However, our results suggest that little direct flow of the immunoglobulin injected into the albumen had occurred to modulate myostatin's biological activity. Currently, however, no information is available regarding the fate of immunoglobulins injected into the albumen during avian egg development, and more studies are needed to address this question.
In conclusion, our results suggest that the presence of our anti-myostatin antibody in the yolk during early incubation period enhances the growth of body and skeletal muscle mass. These results are encouraging because immunoneutralization of myostatin could be a potential means to improve the growth potential of broilers. The maternal transfer of immunoglobulins to the embryo in chicken is well established. Therefore, to make this approach of immunoneutralization feasible for commercial broiler production, it will be interesting to examine whether active-immunization of hen against myostatin is effective in enhancing the posthatch growth of skeletal muscle and body mass.
